Home LiteratureArticle Details
PMID: 19228972 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.

Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, André VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR

Abstract

Huntington disease (HD) is a neurodegenerative disorder caused by an expanded CAG tract in the HD gene. Polyglutamine expansion of huntingtin (htt) results in early, progressive loss of medium spiny striatal neurons, as well as cortical neurons that project to the striatum. Excitotoxicity has been postulated to play a key role in the selective vulnerability of striatal neurons in HD. Early excitotoxic neuropathological changes observed in human HD brain include increased quinolinate (QUIN) concurrent with proliferative changes such as increased spine density and dendritic length. In later stages of the disease, degenerative-type changes are apparent, such as loss of dendritic arborization, a reduction in spine density and reduced levels of 3-hydroxykynurenine and QUIN. It is currently unknown whether sensitivity to excitotoxic stress varies between initiation and progression of disease. Here, we have assessed the excitotoxic phenotype in the YAC128 mouse model of HD by examining the response to excitotoxic stress at different stages of disease. Our results demonstrate that YAC128 mice display enhanced sensitivity to NMDA ex vivo and QUIN in vivo before obvious phenotypic changes. In contrast, 10-month-old symptomatic YAC128 mice are resistant to QUIN-induced neurotoxicity. These findings are paralleled by a significant increase in NMDAR-mediated membrane currents in presymptomatic YAC128 dissociated medium spiny neurons progressing to reduced NMDAR-mediated membrane currents with disease progression. These data highlight the dynamic nature of the mutant htt-mediated excitotoxic phenotype and suggests that therapeutic approaches to HD may need to be altered, depending on the stage and development of the disease.

MeSH Terms
Animals Brain/metabolism,physiopathology Brain Ischemia/genetics,metabolism,physiopathology Cells, Cultured Dendritic Spines/metabolism,pathology Disease Models, Animal Disease Progression Genetic Predisposition to Disease/genetics Huntington Disease/genetics,metabolism,physiopathology Mice Mice, Transgenic N-Methylaspartate/metabolism,toxicity Nerve Degeneration/genetics,metabolism,physiopathology Neurotoxins/metabolism,toxicity Organ Culture Techniques Phenotype Quinolinic Acid/metabolism,toxicity Stress, Physiological/genetics Synaptic Membranes/metabolism,pathology Synaptic Potentials/genetics Synaptic Transmission/drug effects,physiology
Chemicals
Neurotoxins N-Methylaspartate Quinolinic Acid
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
Graham Rona K
Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada V5Z 4H4.
Pouladi Mahmoud A
Joshi Prasad
Lu Ge
Deng Yu
Wu Nan-Ping
Figueroa Bryan E
Metzler Martina
André Véronique M
Slow Elizabeth J
Raymond Lynn
Friedlander Robert
Levine Michael S
Leavitt Blair R
Hayden Michael R
References (84)
84 references, click to expand
  1. Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatum.
    J Neurosci Res. 1979;4(5-6):383-98 PMID: 42811
  2. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease.
    Neuroscience. 1995 Feb;64(4):1007-17 PMID: 7753372
  3. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum.
    J Neurosci. 1995 Jul;15(7 Pt 2):5297-307 PMID: 7623152
  4. Striatal potassium channel dysfunction in Huntington's disease transgenic mice.
    J Neurophysiol. 2005 May;93(5):2565-74 PMID: 15625098
  5. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.
    J Neurosci. 2005 Apr 20;25(16):4169-80 PMID: 15843620
  6. Activation of GABA receptors attenuates neuronal apoptosis through inhibiting the tyrosine phosphorylation of NR2A by Src after cerebral ischemia and reperfusion.
    Neuroscience. 2007 Dec 19;150(4):938-49 PMID: 18022328
  7. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study.
    J Neuropathol Exp Neurol. 1997 Apr;56(4):440-54 PMID: 9100675
  8. Automated deformation analysis in the YAC128 Huntington disease mouse model.
    Neuroimage. 2008 Jan 1;39(1):32-9 PMID: 17942324
  9. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
    J Neurosci Res. 2002 Feb 1;67(3):372-8 PMID: 11813242
  10. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death.
    Annu Rev Neurosci. 1990;13:171-82 PMID: 1970230
  11. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease.
    Neurogenetics. 2005 Feb;6(1):25-8 PMID: 15742215
  12. Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype.
    Hum Mol Genet. 1996 Dec;5(12):1875-85 PMID: 8968738
  13. Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity.
    Brain Res Bull. 2000 May 1;52(1):51-9 PMID: 10779703
  14. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease.
    J Neurosci. 1991 Jun;11(6):1649-59 PMID: 1710657
  15. Depletion of wild-type huntingtin in mouse models of neurologic diseases.
    J Neurochem. 2003 Oct;87(1):101-6 PMID: 12969257
  16. Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons.
    J Neurosci. 1994 Nov;14(11 Pt 1):6667-86 PMID: 7965068
  17. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene.
    Eur J Neurosci. 2001 Nov;14(9):1492-504 PMID: 11722611
  18. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice.
    J Neurophysiol. 2001 Dec;86(6):2667-77 PMID: 11731527
  19. Mice overexpressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid.
    Exp Neurol. 2002 Jul;176(1):262-5 PMID: 12093104
  20. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory.
    Mov Disord. 1996 Mar;11(2):167-73 PMID: 8684387
  21. Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting.
    Neuroscience. 1985 Dec;16(4):799-817 PMID: 2936982
  22. Regulation of dendritic spine stability.
    Hippocampus. 2000;10(5):542-54 PMID: 11075824
  23. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
    J Neurosci Res. 2005 Nov 1;82(3):377-86 PMID: 16211559
  24. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination.
    Stroke. 1986 May-Jun;17(3):472-6 PMID: 3715945
  25. The termination of fibres from the cerebral cortex and thalamus upon dendritic spines in the caudate nucleus: a study with the Golgi method.
    Philos Trans R Soc Lond B Biol Sci. 1971 Sep 30;262(845):429-39 PMID: 4107496
  26. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.
    Neurobiol Dis. 2006 Feb;21(2):392-403 PMID: 16165367
  27. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration.
    Brain Res. 1997 Mar 14;751(1):37-46 PMID: 9098566
  28. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.
    Neurobiol Dis. 2006 Feb;21(2):444-55 PMID: 16230019
  29. NMDA receptor function in mouse models of Huntington disease.
    J Neurosci Res. 2001 Nov 15;66(4):525-39 PMID: 11746372
  30. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways.
    Exp Neurol. 1998 Jul;152(1):34-40 PMID: 9682010
  31. Huntington's disease transgenic mice are resistant to global cerebral ischemia.
    Neurosci Lett. 2002 Dec 13;334(2):99-102 PMID: 12435481
  32. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice.
    J Neurophysiol. 2005 Feb;93(2):758-65 PMID: 15371492
  33. Neurophysiological alterations in caudate neurons in aged cats.
    Brain Res. 1987 Jan 20;401(2):213-30 PMID: 3028574
  34. Postnatal development of a persistent Na+ current in pyramidal neurons from rat sensorimotor cortex.
    J Neurophysiol. 1993 Jan;69(1):290-2 PMID: 8381860
  35. Effects of aging on quinolinic acid lesions in rat striatum.
    Brain Res. 1991 Oct 25;562(2):276-80 PMID: 1837750
  36. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
    Exp Neurol. 2002 May;175(1):297-300 PMID: 12009780
  37. Selective sparing of NADPH-diaphorase-somatostatin-neuropeptide Y neurons in ischemic gerbil striatum.
    Ann Neurol. 1990 Jun;27(6):620-5 PMID: 1972876
  38. Attenuation of focal ischemic brain injury in mice deficient in the epsilon1 (NR2A) subunit of NMDA receptor.
    J Neurosci. 1998 Dec 1;18(23):9727-32 PMID: 9822733
  39. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization.
    Exp Neurol. 1993 Jan;119(1):46-71 PMID: 8432351
  40. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
    Neurobiol Dis. 2006 Jul;23(1):190-7 PMID: 16697652
  41. The corticostriatal pathway in Huntington's disease.
    Prog Neurobiol. 2007 Apr;81(5-6):253-71 PMID: 17169479
  42. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
    Hum Mol Genet. 2003 Jul 1;12(13):1555-67 PMID: 12812983
  43. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease.
    Mol Cell Neurosci. 2004 Mar;25(3):469-79 PMID: 15033175
  44. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model.
    Brain. 2004 Mar;127(Pt 3):505-16 PMID: 14662521
  45. Widespread expression of Huntington's disease gene (IT15) protein product.
    Neuron. 1995 May;14(5):1065-74 PMID: 7748554
  46. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
    J Neurophysiol. 2006 Apr;95(4):2108-19 PMID: 16381805
  47. Cytoplasmic inclusions of Htt exon1 containing an expanded polyglutamine tract suppress execution of apoptosis in sympathetic neurons.
    J Neurosci. 2008 Dec 31;28(53):14401-15 PMID: 19118173
  48. Ischemic damage in the striatum of adult gerbils: relative sparing of somatostatinergic and cholinergic interneurons contrasts with loss of efferent neurons.
    Exp Neurol. 1990 Nov;110(2):209-18 PMID: 1977609
  49. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.
    Neuron. 2002 Mar 14;33(6):849-60 PMID: 11906693
  50. Kynurenic acid is present in the rat brain and its content increases during development and aging processes.
    Neurosci Lett. 1988 Nov 22;94(1-2):145-50 PMID: 2468114
  51. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids.
    Nature. 1976 Oct 7;263(5577):517-9 PMID: 9592
  52. The HD mutation does not alter neuronal death in the striatum of Hdh(Q92) knock-in mice after mild focal ischemia.
    Neurobiol Dis. 2002 Oct;11(1):147-54 PMID: 12460554
  53. Glutamate induces the rapid formation of spine head protrusions in hippocampal slice cultures.
    Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6166-71 PMID: 15831587
  54. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.
    Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8727-32 PMID: 10411943
  55. Glycine site NMDA receptor antagonists provide protection against ischemia-induced neuronal damage in hippocampal slice cultures.
    Brain Res. 1995 Mar 27;675(1-2):38-44 PMID: 7796152
  56. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons.
    Neuron. 1995 May;14(5):1075-81 PMID: 7748555
  57. Huntington disease.
    J R Soc Med. 2005 Dec;98(12):550 PMID: 16319434
  58. Intracellular neurophysiological analysis reveals alterations in excitation in striatal neurons in aged rats.
    Brain Res. 1989 Aug 14;494(2):215-26 PMID: 2776015
  59. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
    J Neurophysiol. 2004 Nov;92(5):2738-46 PMID: 15240759
  60. Accelerated cerebral ischemic injury by activated macrophages/microglia after lipopolysaccharide microinjection into rat corpus callosum.
    Glia. 2005 Apr 15;50(2):168-81 PMID: 15702482
  61. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.
    Cell. 2006 Jun 16;125(6):1179-91 PMID: 16777606
  62. Aging reduces neostriatal responsiveness to N-methyl-D-aspartate and dopamine: an in vitro electrophysiological study.
    Neuroscience. 1996 Aug;73(3):733-50 PMID: 8809794
  63. Strain-dependent decrease in glutamate binding to the N-methyl-D-aspartic acid receptor during aging.
    Neurosci Lett. 1989 Oct 9;104(3):309-13 PMID: 2573018
  64. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.
    J Neurosci. 2003 Feb 1;23(3):961-9 PMID: 12574425
  65. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
    J Neurosci. 2008 Nov 26;28(48):12725-35 PMID: 19036965
  66. Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age.
    Brain Res. 1989 Dec 4;503(2):334-8 PMID: 2514009
  67. Neuropathological classification of Huntington's disease.
    J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77 PMID: 2932539
  68. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.
    Prog Neurobiol. 2007 Apr;81(5-6):272-93 PMID: 17188796
  69. Age-related changes in excitatory amino acid receptors in two mouse strains.
    Neurobiol Aging. 1993 May-Jun;14(3):197-206 PMID: 8391661
  70. Relative sparing of GABAergic interneurons in the striatum of gerbils with ischemia-induced lesions.
    Neurosci Lett. 1992 Jan 20;135(1):53-8 PMID: 1542438
  71. NMDA receptor function and NMDA receptor-dependent phosphorylation of huntingtin is altered by the endocytic protein HIP1.
    J Neurosci. 2007 Feb 28;27(9):2298-308 PMID: 17329427
  72. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances.
    J Neurophysiol. 1998 Jan;79(1):82-94 PMID: 9425179
  73. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology.
    J Exp Med. 2004 Jul 19;200(2):211-22 PMID: 15263028
  74. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.
    J Exp Med. 2008 Aug 4;205(8):1869-77 PMID: 18625748
  75. Repeated asphyxia causes loss of striatal projection neurons in the fetal sheep brain.
    Neuroscience. 1995 Apr;65(3):827-36 PMID: 7609881
  76. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.
    Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11402-7 PMID: 16076956
  77. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract.
    Brain Res. 1978 Jan 13;139(2):381-3 PMID: 146535
  78. Heat shock protein HSP70 increases the resistance of cortical cells to glutamate excitotoxicity.
    Bull Exp Biol Med. 2005 Jul;140(1):1-5 PMID: 16254606
  79. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease.
    Science. 1985 Feb 15;227(4688):770-3 PMID: 3155875
  80. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry.
    J Neurosci. 1991 Dec;11(12):3877-87 PMID: 1836019
  81. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease.
    J Neurosci Res. 1999 Nov 15;58(4):515-32 PMID: 10533044
  82. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
    Neurobiol Dis. 2004 Dec;17(3):455-61 PMID: 15571981
  83. Transient global ischemia in rats yields striatal projection neuron and interneuron loss resembling that in Huntington's disease.
    Exp Neurol. 2000 Dec;166(2):307-23 PMID: 11085896
  84. Selective sparing of NADPH-diaphorase neurons in neonatal hypoxia-ischemia.
    Ann Neurol. 1988 Nov;24(5):670-6 PMID: 2904792
Article Info
Journal
The Journal of neuroscience : the official journal of the Society for Neuroscience
Abbr.
J Neurosci
ISSN
1529-2401
Published
2009-02-18
Pages
2193-204
Language
English
Region
United States
NLM ID
8102140
PMCID
PMC2729178
Subset
IM
Grants
NINDS NIH HHS · R01 NS041574 · United States
NINDS NIH HHS · R01 NS041574-07 · United States
NINDS NIH HHS · NS41574 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com